A5079071634- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Eosinophilic Disorders and Syndromes
- Angiogenesis and VEGF in Cancer
- Fibroblast Growth Factor Research
- Cancer, Hypoxia, and Metabolism
First Affiliated Hospital of Anhui Medical University
2025
Anhui Medical University
2025
Sechenov University
2019
Russian Cancer Research Center NN Blokhin
2019
Hainan Medical University
2007
Abstract Venetoclax, a selective BCL2 inhibitor, is extensively utilized in clinical settings for the treatment of acute myeloid leukemia (AML). However, its efficacy often compromised by development drug resistance. Hence, identification potential venetoclax combination strategies imperative to overcome this acquired In study, we discovered that inhibition METTL3 can synergistically enhance anti-leukemic venetoclax, and capable overcoming resistance vivo experiments various models....
Introduction. Previously we»ve shown that there are typical changes in haematopoiesis diffuse large B-cell lymphoma patients (DLBCL). Attention was paid to the elevation of oxyphylic erythroblasts, as this sign prognostic significance. The aim work see if is possible identify bone marrow erythrokaryocyte maturation stages using flow cytometry method. Materials and methods. Study done 60 DLBCL patients. Elevation oxyphilic erythrobast levels noted 50 (83,3 %). Flow cytometric study were 30 We...
Introduction. Increasing of blast cell percentage in bone marrow diffuse large B-cell lymphoma patients is a sign unfavourable prognosis. We estimated the frequency this phenomenon and made attempts to idenify minimal involvement DLBCL by flow cytometry. Materials methods. Study has been done 60 patients. Diagnosis all cases was according WHO (2008) criteria. Bone study on smears (myelogram). Immunophenotypic with panel B-lineage monoclonal antibodies as well kappa lambda light chains...